{
  "meta": {
    "title": "Diabetes_Part_2",
    "url": "https://brainandscalpel.vercel.app/diabetes-part-2-6ee0c02c.html",
    "scrapedAt": "2025-11-30T11:12:51.668Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 4</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 49-year-old male with type 2 diabetes is on twice weekly dialysis due to chronic kidney disease. Which of the following oral hypoglycemic agents would be safe to use in this patient?<br>1. Acarbose<br>2. Repaglinide<br>3. Linagliptin<br>4. Glimepiride</span></p>",
      "unique_key": "DT1186925",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186925,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Both acarbose and glimepiride are contraindicated in renal insufficiency.</strong></p>\n<p><strong>Acarbose:</strong></p>\n<ul>\n<li>Acarbose is an alpha-glucosidase inhibitor which decreases post-prandial blood glucose by inhibiting absorption of monosaccharides.</li>\n<li>Acarbose is contraindicated in inflammatory bowel disease, renal failure and decompensated hepatic failure.</li>\n</ul>\n<p><strong>Repaglinide:</strong></p>\n<ul>\n<li>Repaglinide is a meglitinide analogue, which is short-acting and used for control of post-prandial blood glucose.</li>\n<li>Repaglinide undergoes hepatic clearance; hence is safe in individuals with chronic kidney disease.</li>\n<li>Repglinide is the only nonsulfonylurea Insulin secretagogue, which is not contraindicated for use in renal patients.</li>\n</ul>\n<p><strong>Linagliptin:</strong></p>\n<ul>\n<li>Linagliptin is the only DPP-4 inhibitor approved for use in renal failure.</li>\n<li>Linagliptin is well tolerated and does not cause hypoglycemia.</li>\n</ul>\n<p><strong>Glimepiride:</strong></p>\n<ul>\n<li>Most sulfonylureas are metabolised in the liver to compounds that are cleared by the kidneys. Thus, their use in individuals with significant hepatic or renal dysfunction is not advisable.</li>\n<li>For patients with chronic kidney disease requiring an insulin secretagogue, the shorter-acting sulfonylureas glimepiride or glipizide or the glinide repaglinide may be used with caution.</li>\n</ul>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">A few dot and blot haemorrhages</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Some hard exudates > 1 disc diameter from the fovea</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Cataract</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">New vessels on the disc</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 57-year-old male, with recently diagnosed type-2 diabetes mellitus, presents to the clinic for his first assessment. Fundoscopic examination showed retinal changes. Which of the following findings necessitate the need for immediate referral to an ophthalmologist?</span></p>",
      "unique_key": "DT1186928",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186928,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>New vessels anywhere in the fundus are a feature of proliferative retinopathy and, as new vessels have a risk of haemorrhage and can threaten sight, they should be referred urgently to the ophthalmologist.</p>\n<ul>\n<li>The appearance of neovascularisation in response to retinal hypoxemia is the hallmark of proliferative diabetic retinopathy.</li>\n<li>These newly formed vessels appear near the optic nerve and/or macula and rupture easily, leading to vitreous haemorrhage, fibrosis, and ultimately retinal detachment.</li>\n<li>Thus, severe vision loss is primarily the result of progressive diabetic retinopathy.</li>\n<li>The most effective therapy for diabetic retinopathy is prevention.</li>\n<li>Intensive glycemic and blood pressure control will delay the development and slow the progression of retinopathy.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>A few dot and blot haemorrhages (Option A), some hard exudates &gt; 1 disc diameter from the fovea (Option B):</strong>  Background diabetic retinopathy consists of dot and blot haemorrhages and hard exudates. Patients do not need to be referred to the ophthalmologist unless these are within 1 disc diameter of the fovea. This can be monitored annually at the routine clinic. Soft exudates suggest retinal ischaemia, which would require routine referral to the ophthalmologist.</p>\n<p><strong>Cataract (Option C):</strong> Cataracts appear about 10 years earlier in type-2 diabetes than in non-diabetic patients. If the vision is significantly affected, the patients warrant routine and not urgent referral to the ophthalmologist.</p>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">a-iv, b-iii, c-i, d-ii</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">a-ii, b-iv, c-i, d-iii</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">a-iii, b-ii, c-i, d-iv</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">a-iii, b-iv, c-i, d-ii</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following insulins with their duration of action:<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025091889d99aee-1745-4b2d-8b89-46876d0dd408.png\"></span></p>",
      "unique_key": "DT1186929",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186929,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918b42f2d7d-3c90-4a28-9a98-1a64bf9b7090.png\">\n<p><strong>Insulin preparations:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918839cda2b-f6fc-4209-9d09-edf161435d98.png\">\n<ul>\n<li>The longest-acting insulin is degludec.</li>\n<li>Most of the insulins are clear except NPH insulin, which is cloudy white.</li>\n</ul>",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduced post-prandial hypoglycaemia</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Has a rapid onset and shorter duration</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduced nocturnal hypoglycaemia</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased ability to undertake exercise more easily</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 16-year-old girl with Type 1 diabetes is currently on 30/70 mixed insulin taken twice daily. Her parents report irregular food habits and hypoglycaemic episodes during midnight. On evaluation, her HbA1c was 9.4%. You plan to switch her to a basal-bolus insulin regimen using insulin glargine/aspart. Which of the following best represents the main advantage of insulin glargine?</span></p>",
      "unique_key": "DT1186930",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186930,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Insulin glargine provides a steady, peakless release of insulin over 24 hours. This reduces the risk of nocturnal hypoglycemia.</p>\n<ul>\n<li>Insulin glargine is an insulin analogue produced by substitution of glycine for asparagine at A21 and by adding two arginines to the B chain.</li>\n<li>It is formulated at pH 4, but when injected, the transformation to pH 7 causes the insulin crystals to precipitate, leading to a slowly released, <strong>peakless profile</strong>.</li>\n<li>The main advantage of insulin glargine is in reduction of nocturnal hypoglycaemia.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Reduced post-prandial hypoglycaemia (Option A): </strong>Short-acting analogues like regular insulin are useful in reducing post-prandial hypoglycaemia, as their profile is more in keeping with physiological insulin release.</p>\n<p><strong>Has a rapid onset and shorter duration (Option B): </strong>Glargine is basal insulin, which is long acting and provides a constant, low level of insulin control for fasting blood glucose levels. Lispro and aspart are examples of rapid-acting insulin.</p>\n<p><strong>Provides stable 24-hour basal insulin coverage (Option D):</strong> This is true, and is a benefit of glargine. However, in this context, as the clinical concern is nighttime hypoglycaemia, Option C is a more specific answer.</p>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Type 1 diabetes</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">MODY 3</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">MODY 5</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">LADA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 21-year-old male presents with fatigue, polyuria, thirst and recurrent candidal infections. He has a BMI of 22 and reports a strong family history of Type 2 diabetes. On evaluation, fasting blood glucose was 150 mg/dl and HDL was elevated. Islet cell, GAD, and insulin antibodies were negative. Renal and liver function tests were also within normal limits. Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1186931",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186931,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The most likely diagnosis <strong>is MODY 3</strong>, as suggested by the patient's young age, strong family history of diabetes, elevated fasting blood glucose and HDL, and absence of islet cell autoantibodies.</p>\n<ul>\n<li><strong>MODY 3</strong> is the commonest form of MODY, with age of onset between the 10-30 year age group.</li>\n<li>They present with an <strong>autosomal dominant </strong>mode of transmission, and MODY 3 is caused by mutations in <strong>hepatocyte nuclear transcription factor HNF-1&alpha;.</strong></li>\n<li>MODY 3 is characterised by raised HDL cholesterol, preserved insulin sensitivity and a low renal threshold (glycosuria).</li>\n<li>Individuals with MODY 3 have a progressive decline in glycemic control but may respond to sulfonylureas.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Type 1 diabetes (Option A): </strong>Type 1 DM is the result of interactions of genetic, environmental, and immunologic factors that ultimately lead to immune-mediated destruction of the pancreatic beta cells and insulin deficiency. Thus, type 1 DM is characterised by the presence of autoantibodies against beta cells.</p>\n<p><strong>MODY 5 (Option C):</strong> MODY results from mutation of hepatocyte nuclear transcription factor 1&beta;. These individuals often have other abnormalities such as renal cysts, mild pancreatic exocrine insufficiency, and abnormal liver function tests.</p>\n<p><strong>LADA (Option D): </strong>LADA patients develop hyperglycemia in their early 30s to late 40s and are characterised by the <strong>presence of pancreatic autoantibodies</strong>, such as anti-GAD antibodies.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202404231c0ec736-ddf2-4063-9ca1-2982e0b3e34c.jpg\">",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Tolbutamide</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Gliclazide</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Chlorpropamide</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Glipizide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 38-year-old woman with type 2 maturity-onset diabetes mellitus is started on sulphonylurea. Shortly after consuming alcohol, she develops severe facial flushing and sweating. Which of the following drugs is most likely responsible for this reaction?</span></p>",
      "unique_key": "DT1186932",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186932,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The facial flushing and sweating following alcohol intake are typical of disulfiram like reactions, which occur with chlorpropamide.</p>\n<ul>\n<li>First-generation sulfonylureas include chlorpropamide, tolazamide, and tolbutamide.</li>\n<li>They have a longer half-life, a greater incidence of hypoglycemia, and more frequent drug interactions.</li>\n<li>Second-generation sulfonylureas <strong>(glimepiride and glipizide)</strong> have a more rapid onset of action and better coverage of the postprandial glucose rise, but the shorter half-life of some agents may require more than once-a-day dosing.</li>\n<li>Among sulphonylureas, <strong>chlorpropamide</strong> is mainly associated with <strong>disulfiram like reaction</strong> following alcohol intake, although a lesser reaction may be seen with other SUs.</li>\n</ul>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases glycogenolysis in muscle</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Induces the synthesis of phosphofructokinase</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Stimulates acetyl-CoA carboxylase</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Activates adenylate cyclase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A young patient with hypoglycaemia is administered glucagon. Which of the following actions of glucagon would be most likely to be effective in treating this condition?</span></p>",
      "unique_key": "DT1186933",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186933,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Glucagon activates adenylate cyclase, which increases cAMP, leading to glycogenolysis and gluconeogenesis in the liver, resulting in hypoglycemia.</p>\n<ul>\n<li>Glucagon acts mainly on the liver and has no action on muscle. It increases glycogenolysis and gluconeogenesis and also stimulates lipolysis in adipose tissue (Option A ruled out).</li>\n<li>Adenylate cyclase is a key enzyme involved in the breakdown of glycogen polymers to increase availability of glucose.</li>\n<li>Activation of this and other enzymes is responsible for restoring blood glucose levels in this case.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Induces the synthesis of phosphofructokinase (Option B): </strong>Phosphofructokinase is a key enzyme in glycolysis and is inhibited by glucagon. This results in further worsening of hypoglycemia.</p>\n<p><strong>Stimulates acetyl-CoA carboxylase (Option C):</strong> Acetyl-CoA is a major enzyme in fatty acid synthesis. Glucagon inhibits acetyl-CoA carboxylase, while insulin stimulates acetyl-CoA carboxylase to increase the synthesis of fatty acids. Glucagon acts via cyclic AMP to stimulate lipolysis, producing free fatty acids that can act as a major source of energy.</p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Semaglutide promotes weight gain and increases appetite</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Imeglimin acts by modulating mitochondrial function</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Icodec is a once-weekly long-acting insulin analogue</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Colesevelam is the bile-acid sequestrant approved for use in Type 2 Diabetes mellitus</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements regarding newer agents used in the management of diabetes is not true?</span></p>",
      "unique_key": "DT1186935",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186935,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Semaglutide</strong> is a GLP-1 agonist which promotes weight loss and decreases appetite.<strong><br /> </strong></p>\n<ul>\n<li>Semaglutide is a long-acting <strong>GLP-1 receptor agonist</strong>.</li>\n<li>GLP-1 receptor agonists increase glucose-stimulated insulin secretion, suppress glucagon, and <strong>slow gastric emptying</strong>.</li>\n<li>These agents do not promote weight gain; in fact, most patients experience modest <strong>weight loss and appetite suppression.</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Imeglimin acts by modulating mitochondrial function (Option A):</strong> Imeglimin acts by modulating mitochondrial function to inhibit Complex I of the respiratory chain. Imeglimin improves insulin sensitivity of peripheral tissues and enhances glucose-stimulated insulin secretion.</p>\n<p><strong>Icodec is a once-weekly long-acting insulin analogue (Option C). </strong>Insulin icodec, which is in development but not yet FDA approved, is considered ultra long acting, with a 1-week half-life and once-weekly dosing, and may provide advantages over daily injection for some patients.</p>\n<p><strong>Colesevelam is the bile-acid sequestrant approved for use in Type 2 Diabetes mellitus (Option). </strong>Colesevelam is a second-generation bile acid sequestrant approved for treatment of hypercholesterolemia and may be used for treatment of type 2 diabetes as an adjunct to diet and exercise. In clinical trials, colesevelam reduced A1c by 0.5% when added to metformin, sulfonylurea, or insulin treatment in type 2 diabetic patients.</p>",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Losartan</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Lisinopril</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrochlorothiazide</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Atenolol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old man with type-2 diabetes mellitus and hypertension presents for regular follow-up. On evaluation, his BP was elevated, and a second antihypertensive drug was added. Which of the following antihypertensive drugs is least likely to be prescribed for this patient?</span></p>",
      "unique_key": "DT1186936",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186936,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Hydorcholorothiazide, a thiazide diuretic, is associated with impaired glucose tolerance and is thus usually not recommended for the treatment of hypertension in patients with diabetes mellitus.</p>\n<ul>\n<li>Thiazides cause<strong> impaired glucose tolerance </strong>by:\n<ul>\n<li>Causing hypokalemia, which reduces insulin secretion</li>\n<li>Increasing insulin resistance</li>\n<li>Reducing peripheral glucose utilisation</li>\n</ul>\n</li>\n<li>While thiazides are effective for lowering blood pressure, their diabetogenic effect makes it a concern in patients already struggling with glycemic control.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Losartan (Option A), Lisnopril (Option B): </strong>Losartan (ARBs) and lisnopril (ACE inhibitors) are generally considered safe in diabetic patients due to renal protection and minimal metabolic effects.</p>\n<p><strong>Atenolol (Option D): </strong>Beta blockers like atenolol inhibit glycogenolysis and delay recovery from hypoglycemia. They also mask warning signs and symptoms of hypoglycemia. Thus, they should be used with caution in diabetic patients. However, beta blockers are not commonly associated with hyperglycemia.</p>",
      "correct_choice_id": 83,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Improves satiety</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Weight neutral</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase glucose-mediated insulin release</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with type 2 DM is started on liraglutide. Which of the following effects is not associated with  Liraglutide?</span></p>",
      "unique_key": "DT1186937",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186937,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Liraglutide promotes weight loss and is useful in obese patients with diabetes.</p>\n<ul>\n<li>Liraglutide is a <strong>GLP-1 analogue</strong> administered as once-daily subcutaneous injection</li>\n<li>The actions of Liraglutide include:\n<ul>\n<li>Increases glucose-dependent insulin secretion<em> (Option C ruled out)</em></li>\n<li>Promotes weight loss</li>\n<li>Improves satiety <em>(Option A ruled out)</em></li>\n<li>Mild reduction in blood pressure</li>\n<li>Decreases cardiovascular mortality</li>\n<li>Improves liver enzymes in NASH</li>\n</ul>\n</li>\n<li>Liraglutide has been approved for <strong>treatment of obesity</strong> for subjects aged &gt; 12 years.</li>\n<li>Liraglutide is used at a dose of 3 mg for weight reduction, while the dose range for diabetes treatment is 0.6-1.8 mg.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509184be88c22-ec95-4d57-b9e0-7425ff3ed995.png\">",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">HBA1C < 7%</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Pre-prandial plasma glucose of 70-110 mg/dl</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Peak post-prandial plasma glucose < 180 mg/dl</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Blood pressure < 130/80 mmHg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">According to the ADA guidelines, which of the following is not a recommended treatment goal for patients with type 2 diabetes mellitus?</span></p>",
      "unique_key": "DT1186938",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186938,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>As per ADA guidelines, the target pre-prandial plasma glucose level is<strong> 80-130 mg/dL.</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509182e5b2e63-0df6-47b0-9cb8-d4516033f940.png\">\n<p>For individuals with diabetes and hypertension at higher cardiovascular risk, a blood pressure target of <strong>&lt;130/80mmHg</strong> may be appropriate, if it can be safely attained</p>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Empagliflozin and Dulaglutide</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin and Sitagliptin</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Linagliptin and Acarbose</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin and Insulin glargine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In an obese patient with Type 2 Diabetes, which of the following medications would aid in weight loss for these patients?</span></p>",
      "unique_key": "DT1186939",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186939,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Empagliflozin and Dulaglutide</strong> are oral hypoglycemic agents that aid in weight loss.</p>\n<ul>\n<li>The class of oral hypoglycemic drugs that aid in weight loss include GLP-1 analogues (Dulaglutide), SGLT-2 inhibitors (Empagliflozin), in addition to Metformin.</li>\n<li>DPP-4 inhibitors (Linagliptin, Sitagliptin) are weight-neutral.</li>\n<li>Insulin and insulin secretagogues (sulfonyl ureas, meglitinide analogues) and thiazolidinediones (due to fluid retention) promote weight gain.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918048dae81-f489-4e5a-ac74-a900b7b1ae81.png\">",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic ketoacidosis</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-ketotic hyperosmolar coma</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic nephropathy</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Ventricular tachycardia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old male with diabetes and congestive heart failure is admitted in a comatose state. His current medications include metformin and amiloride. Blood investigations revealed:<br>Na+ 152 mmol/l; K+ 5.0 mmol/l<br>Chloride 115 mmol/l ; Bicarbonate 30 mmol/l<br>Glucose 520 mg/dl<br>Creatinine 1.9 mg/dl<br>pH 7.35<br>Based on the findings, what is the most probable diagnosis?</span></p>",
      "unique_key": "DT1186940",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186940,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient's presentation and findings are most consistent with <strong>non-ketotic hyperosmolar coma.</strong> The renal impairment in this case is due to combined use of metformin and amiloride.</p>\n<p>Non-ketotic hyperosmolar coma is characterised by <strong>hyperosmolality</strong> and absence of ketoacidosis.</p>\n<p>Patients present with <strong>marked hyperglycemia</strong> with <strong>stupor or coma</strong>.</p>\n<p><strong>Laboratory findings:</strong></p>\n<ul>\n<li>Normal pH, PCO2, HCO3</li>\n<li>Sometimes, patients may develop lactic acidosis, and pH will be low.</li>\n<li>Negative for urine ketone bodies.</li>\n</ul>\n<p><strong>Treatment includes </strong>fluid replacement, insulin administration and electrolyte monitoring.</p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Diabetic ketoacidosis (Option A): </strong>The bicarbonate level and blood pH would both be low in patients with diabetic ketoacidosis, but in this case there is no significant acidosis and the bicarbonate level.</p>\n<p><strong>Diabetic nephropathy (Option C): </strong>A patient with diabetic nephropathy will have raised blood glucose levels and deranged renal parameters. But it is unlikely to cause a comatose state.</p>\n<p><strong>Ventricular tachycardia (Option D): </strong>Ventricular arrhythmias result from electrolyte imbalance, like hyperkalemia, hypomagnesemia, and hypocalcemia. But, arrhythmia at potassium level of 5 mmol/L is very unlikely. Further arrhythmias present with symptoms like palpitation, syncope.</p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin glargine</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Dapagliflozin</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Saxagliptin</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Liraglutide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old obese female with a 10-year history of Type 2 Diabetes mellitus is evaluated for exertional dyspnea and orthopnea. Echocardiogram revealed heart failure with preserved ejection fraction. She is currently on Metformin 1.5 gm/day and Glimepiride 2 mg BD with an HBA1C of 8.1%. What of the following would be the most appropriate additional agent for glycemic control in this patient?</span></p>",
      "unique_key": "DT1186942",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186942,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Dapagliflozin would be appropriate in this patient, as it has proven to reduce cardiovascular risk in patients with diabetes.</p>\n<ul>\n<li>DAPA-HF trial has demonstrated that the use of Dapagliflozin in patients with heart failure and reduced ejection fraction, irrespective of the presence of Diabetes mellitus, has <strong>reduced worsening of heart failure</strong> and decreased mortality from cardiovascular causes.</li>\n<li>Based on this, SGLT2 inhibitors are considered as a foundational therapy for HF alongside ARNI, beta-blockers, and mineralocorticoid receptor antagonists.</li>\n<li>The weight loss and diuretic effect provided by SGLT2 inhibitor addition would also benefit the patient.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Insulin glargine (Option A):</strong> Insulin glargine would benefit in obtaining glycemic control, but has no added benefit in heart failure improvement</p>\n<p><strong>Saxagliptin (Option C): </strong>Saxagliptin has been shown to worsen the cardiovascular outcomes in patients with heart failure (SAVOR-TIMI trial).</p>\n<p><strong>Liraglutide (Option D): </strong>Liraglutide (GLP-1 analogue) has been shown to decrease progression of coronary artery disease, new incident MI and cardiovascular mortality, but is inferior to SGLT2 inhibitors in patients with heart failure.</p>",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Tirzepatide</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Teduglutide</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Imeglimin</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Dorzagliatin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following agents used in the management of Diabetes mellitus act as both a dual GLP-1 and GIP agonist?</span></p>",
      "unique_key": "DT1186943",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186943,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Tirzepatide is the <strong>dual GLP1 and GIP agonist</strong> approved for treatment of both DM and obesity.</li>\n<li>Tirzepatide is a stronger agonist of the GIP than the GLP1 receptor. It potentiates GLP1-induced weight loss (without GIP itself reducing energy intake).</li>\n<li>It is associated with weight-independent<strong> insulin sensitisation</strong> and greater stimulation of insulin secretion.</li>\n<li>Taking a 15 mg weekly dose is known to reduce HbA1c by 2.3% from a baseline of 8.3%..</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Teduglutide (Option B): </strong>Teduglutide, a glucagon-like peptide 2 analogue used in short bowel syndrome. It enhances crypt cell proliferation and villus hyperplasia, and increases nutrient and fluid and electrolyte absorption.</p>\n<p><strong>Imeglimin (Option C): </strong>Imeglimin is an oxidative phosphorylation inhibitor which acts by modulating mitochondrial function. It improves insulin sensitivity of peripheral tissues and enhances glucose-stimulated insulin secretion. It is also a novel agent used in the treatment of diabetes.</p>\n<p><strong>Dorzagliatin (Option D): </strong>Dorzagliatin is the glucokinase activator used in management of DM.</p>",
      "correct_choice_id": 141,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Acanthosis nigricans</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Dermatitis herpetiformis</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Granuloma annulare</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Necrobiosis lipoidica</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 22-year-old woman with type-1 diabetes presents with a slowly developing lesion on her shin. It initially appeared erythematous patch, but over time became yellowish and has now begun to ulcerate. What is the likely diagnosis?</span></p>",
      "unique_key": "DT1186944",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186944,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>A slowly progressive lesion in skin beginning as an erythematous patch and finally ulcerating in a diabetic is characteristic of necrobiosis lipoidica.</p>\n<ul>\n<li>Necrobiosis lipoidica diabeticorum is an uncommon disorder, accompanying diabetes in predominantly young women.</li>\n<li>This usually begins in the <strong>pretibial region </strong>as an erythematous plaque or papules.</li>\n<li>These lesions gradually enlarge, darken, and develop irregular margins, with <strong>atrophic centres</strong> and <strong>central ulceration</strong>. They are often painful.</li>\n<li>Biopsy specimens show <strong>necrobiosis of collagen</strong> and granulomatous inflammation.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Acanthosis nigricans (Option A):</strong> Acanthosis nigricans is associated with insulin resistance and may occur in those with type-2 diabetes. They appear as hyperpigmented velvety plaques seen on the neck, axilla, or extensor surfaces.</p>\n<p><strong>Dermatitis herpetiformis (Option B):</strong> Dermatitis herpetiformis is a skin disorder that is highly associated with celiac disease. It is characterised by intensely pruritic, papulovesicular lesions symmetrically distributed over extensor surfaces.</p>\n<p><strong>Granuloma annulare (Option C): </strong>This is also a skin manifestation of DM. Grauloma annulare is normally diffuse in diabetes and occurs as a ring of erythematous plaques on the extremities or trunk</p>",
      "correct_choice_id": 154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-GAD</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-Tyrosine phosphatase</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti IA2</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti ZnT8</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following autoantibodies in Type 1 Diabetes Mellitus is known to have the highest rate of persistence over time?</span></p>",
      "unique_key": "DT1186945",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186945,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Anti-GAD has the highest persistence. Rate in Type 1 DM after initial diagnosis</p>\n<ul>\n<li>Pathophysiology of Type 1 DM involves the autoimmune-mediated destruction of pancreatic islet cells.</li>\n<li>Islet cell autoantibodies serve as a marker of the autoimmune process of type 1 DM, including:\n<ul>\n<li>Anti-GAD antibody</li>\n<li>Anti IA-2</li>\n<li>Anti ICA (Islet cell antigen)</li>\n<li>Anti ZnT-8</li>\n</ul>\n</li>\n<li>Anti-GAD is also the most common antibody identified in subjects with Type 1 DM.</li>\n<li>Anti-IA2 antibodies, also known as anti-tyrosine phosphatase, are the earliest appearing antibody in Type 1 DM and have the highest risk of progression to overt DM.</li>\n<li>Anti-ZnT8 are antibodies against zinc transporter 8, which plays a crucial role in insulin storage in beta cells.</li>\n</ul>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Erythema chronicum migrans</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Acanthosis nigricans</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Necrobiosis lipoidica</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Necrolytic migratory erythema</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old female with diabetes presents with painful erythematous lesions and blisters over the groin. Investigations revealed anaemia and high glucagon levels. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1186946",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186946,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The presentation of painful, erythematous groin lesions in a diabetic female with anaemia and elevated glucagon levels is characteristic of necrolytic migratory erythema, a hallmark manifestation of glucagonoma syndrome.</p>\n<p><strong>Glucagonoma:</strong></p>\n<ul>\n<li>Patients with glucagonoma syndrome typically present with glucose intolerance, weight loss and anaemia; sometimes angular stomatitis.</li>\n<li>Patients with glucagonoma most commonly present with a characteristic dermatitis, called <strong>necrolytic migratory erythema</strong>.</li>\n<li>The rash usually involves <strong>intertriginous sites</strong>, especially in the groin or buttocks, and can wax and wane.</li>\n<li>The lesion starts as an indurated erythema. Within a few days, blisters will cover the surface of the skin, which then crust and heal, leaving hyperpigmented skin.</li>\n<li>This process takes 7-14 days with lesions developing in one area while others are resolving.</li>\n<li>The diagnosis of glucagonoma can be confirmed by demonstrating an <strong>increased plasma glucagon level,</strong> generally in excess of 1000 pg/mL.</li>\n<li>Surgical cure rate of glucagonoma is as low as 5%, due to metastases many years before presentation.</li>\n<li>Octreotide improves the skin rash but may have a detrimental effect on glucose control; combination chemotherapy with streptazocin and 5-fluorouracil (5-FU) gives good palliative results, as does hepatic embolisation.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024100118d250a9-675e-42ee-b632-b77ded08891b.jpeg\"></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Erythema chronicum migrans (Option A): </strong>This is the characteristic lesion seen in Lyme disease at the site of a tick bite. The lesion begins as papules expanding to erythematous annular lesions with central clearing.</p>\n<p><strong>Acanthosis nigricans (Option B): </strong>Acanthosis nigricans is associated with severe insulin resistance and may occur in those with type-2 diabetes. They appear as hyperpigmented velvety plaques seen on the neck, axilla, or extensor surfaces.</p>\n<p><strong>Necrobiosis lipoidica (Option C):</strong> Necrobiosis lipoidica usually accompanies diabetes in predominantly young women. This usually begins in the pretibial region as an erythematous plaque or papules, which gradually develop irregular margins, with atrophic centres and central ulceration.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025091825f15aae-a4da-4915-8ee9-f046c466dfb7.png\">",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Rapid improvement in blood glucose levels</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Total cholesterol 202 mg/dl</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Triglyceride levels of 185 mg/dl</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Stopping smoking</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old man with type-2 diabetes presents with background diabetic retinopathy. His HB A1c has been consistently above 9% for the past 5 years. Which of the following factors may impact most negatively on the prognosis of his retinopathy?</span></p>",
      "unique_key": "DT1186947",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186947,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Rapid improvement in blood glucose levels may be associated with paradoxical worsening of pre-existing diabetic retinopathy.</p>\n<p><strong>Diabetic retinopathy:</strong></p>\n<ul>\n<li>Diabetic retinopathy is the leading cause of blindness in people of working age.</li>\n<li><strong>Severe vision loss</strong> is primarily the result of <strong>progressive diabetic retinopathy</strong>, which leads to significant macular oedema and new blood vessel formation.</li>\n<li>Rapidly deteriorating visual acuity, hard exudates encroaching on the macula, preproliferative changes or <strong>new-vessel formation </strong>are all indicators for early referral to an ophthalmologist.</li>\n</ul>\n<p><strong>Risk factors:</strong></p>\n<ul>\n<li>Duration of DM and degree of glycemic control are the best predictors of the development of retinopathy; hypertension, nephropathy, and dyslipidemia are also risk factors. (Option B, C ruled out)</li>\n<li>Although there is genetic susceptibility for retinopathy, it confers less influence than either the duration of DM or the degree of glycemic control.</li>\n<li>Smoking does not affect the prognosis of retinopathy. (Option D ruled out.)</li>\n</ul>\n<p><strong>Management:</strong></p>\n<ul>\n<li>Intensive glycemic and blood pressure control will delay the development and slow the progression of retinopathy in individuals with either type 1 or type 2 DM.</li>\n<li>Paradoxically, during the first 6-12 months of improved glycemic control, established diabetic retinopathy may transiently worsen.</li>\n<li>Fortunately, this progression is temporary, and in the long term, improved glycemic control is associated with less diabetic retinopathy.</li>\n</ul>",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">The condition results from loss of protective sensation</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Most commonly affects weight-bearing joints</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Joint aspiration typically shows abundant neutrophils</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">The primary focus of treatment is to stabilise the joint</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old farmer with long-standing type-1 DM is brought to the clinic by his wife with complaints of limping and deformity of his ankle. On examination, the ankle was warm, swollen and non-tender with crepitus and palpable bony debris. X-ray revealed gross joint destruction and apparent dislocation. While inflammatory markers were within normal range, his HbA1c was 9%. All of the following are true about the most likely diagnosis, except:</span></p>",
      "unique_key": "DT1186948",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186948,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The above clinical features in a patient with long-standing uncontrolled diabetes strongly suggest <strong>Charcot's arthropathy. </strong>Typically, joint aspiration reveals sterile clear synovial fluid.</p>\n<ul>\n<li>Charcot neuroarthropathy is a disabling condition characterised by progressive <strong>degeneration of the weight-bearing joints</strong> and bones of the foot. (Option B ruled out.)</li>\n<li>It occurs as a result of<strong> loss of protective sensation</strong>, which leads to the destruction of foot and ankle joints and surrounding bony structures. (Option A ruled out.)</li>\n<li>Diagnosis can be made clinically with a warm and erythematous foot with erythema that decreases with foot elevation.</li>\n<li>Radiographs often reveal obliteration of joint space and fragmentation of both articular surfaces of a joint, leading to subluxation or dislocation.</li>\n<li>The primary focus of treatment is to stabilise the joint. Treatment of the underlying disorder, even if successful, does not usually affect established joint disease. Braces and splints are helpful. (Option Druled out)</li>\n</ul>",
      "correct_choice_id": 191,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiazides</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">ACE inhibitors</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Atypical antipsychotics</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Tricyclic antidepressants</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old hypertensive male with a history of psychiatric illness is evaluated for impaired glucose tolerance. He is currently on antihypertensives and psychiatric medications. Which of the following drug classes is most commonly associated with development of impaired glucose tolerance?</span></p>",
      "unique_key": "DT1186949",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186949,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Atypical antipsychotics are associated with impaired glucose tolerance and may increase the risk of developing type 2 diabetes in patients taking them.</p>\n<ul>\n<li>Antipsychotic agents as a group produce greater adverse effects on glucose regulation, independent of effects on obesity.</li>\n<li>Clozapine, olanzapine, and quetiapine seem more likely to cause <strong>hyperglycemia</strong>, weight gain, and hypertriglyceridemia than other atypical antipsychotic drugs.</li>\n<li>Close monitoring of plasma glucose and lipid levels is indicated with the use of these agents.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Thiazide (Option A):</strong> Thiazides are known to impair glucose tolerance. However, their effects are mild and dose-dependent. Thus, thiazides are continued to be used in diabetic patients with close monitoring.</p>\n<p><strong>ACE inhibitors (Option B): </strong>ACE inhibitors like ramipril reduce progression to type-2 diabetes; this is thought to be mediated by a reduction in insulin resistance.</p>\n<p><strong>Tricyclic antidepressants (Option D): </strong>Tricyclic antidepressants result in weight gain nd increased appetite, but they are not associated with glucose metabolism.</p>",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic distal symmetric sensorimotor polyneuropathy</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Lumbosacral radiculoplexopathy</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Cranial mononeuropathy</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic autonomic neuropathy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following best describes Bruns-Garland syndrome?</span></p>",
      "unique_key": "DT1186950",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186950,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Bruns' garland syndrome</strong> is also known as diabetic amyotrophy or lumbosacral radiculoplexopathy.</li>\n<li>Typically, patients present with severe pain in the low back, hip and thigh in one leg.</li>\n<li>Atrophy and <strong>asymmetrical, painful weakness</strong> involving quadriceps, iliopsoas and adductors of the thigh, sparing the hamstring muscles of the affected leg, become apparent within a few days or weeks.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Diabetic distal symmetric sensorimotor polyneuropathy (Option A):</strong> Diabetic distal Sensory and Sensorimotor Polyneuropathy (DSPN) is the most common form of diabetic neuropathy and manifests as sensory loss beginning in the toes that gradually progresses over time up the legs and into the fingers and arms.</p>\n<p><strong>Cranial mononeuropathy (Option B):</strong> In regard to cranial mononeuropathies, seventh nerve palsies are relatively common but may have other, nondiabetic etiologies. In diabetics, a third nerve palsy is most common, followed by sixth nerve and, less frequently, fourth nerve palsies. Diabetic third nerve palsies are characteristically pupil-sparing.</p>\n<p><strong>Diabetic autonomic neuropathy (Option D): </strong>Autonomic neuropathy is typically seen in combination with DSPN. The autonomic neuropathy can manifest as abnormal sweating, dysfunctional thermoregulation, dry eyes and mouth, pupillary abnormalities, cardiac arrhythmias, and postural hypotension.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li>The most common form of Diabetic neuropathy is the distal symmetric sensorimotor peripheral neuropathy.</li>\n<li>Most common cranial nerve involvement in Diabetes mellitus is Oculomotor nerve, followed by abducens and facial nerves.</li>\n</ul>",
      "correct_choice_id": 212,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Development of hypertension is strongly linked to a genetically inherited variant of red cell sodium-lithium counter-transport activity</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Good hypertensive control has a weaker effect on macrovascular outcomes than good tight glucose control</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypertension in type-2 diabetes is primarily associated with hyperinsulinaemia and insulin resistance</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiazide diuretics are the treatment of choice in patients with hypertension and microalbuminuria</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old diabetic patient currently on metformin and gliclazide presents for routine follow-up. He has a BMI of 31 and his blood pressure is 158/92 mmHg. Which of the following statements relates to hypertension in type 2 diabetes?</span></p>",
      "unique_key": "DT1186951",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186951,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In type 2 diabetes, insulin resistance and compensatory hyperinsulinaemia play a key role in the pathogenesis of hypertension.</p>\n<ul>\n<li>Hyperinsulinaemia directly stimulates sympathetic nervous system activity, increasing renal sodium reabsorption and promoting <strong>vascular smooth muscle proliferation</strong>.</li>\n<li><strong>Insulin resistance </strong>is also associated with the reduced activity of nitric oxide synthase, leading to <strong>reduced vasodilatation </strong>in response to vascular stress.</li>\n<li>All of these are contributors to the development of hypertension.</li>\n<li>Hypertension can accelerate other complications of DM, particularly CVD, nephropathy, and retinopathy.</li>\n<li>In targeting a goal of blood pressure of <strong>&lt;140/90 mmHg,</strong> therapy should first emphasise lifestyle modifications such as weight loss, exercise, stress management, and sodium restriction.</li>\n<li>In some younger individuals or those with increased cardiovascular risk, the provider may target a blood pressure of &lt;130/80 mmHg.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Development of hypertension is strongly linked to a genetically inherited variant of red cell sodium-lithium counter-transport activity (Option A):</strong> Red cell sodium-lithium counter-transport activity abnormalities are associated with the early development of hypertension in type-1 diabetes. This dysfunction reflects increased sodium reabsorption in the kidneys, which can contribute to elevated blood pressure.</p>\n<p><strong>Thiazide diuretics are the treatment of choice in patients with hypertension and microalbuminuria (Option D):</strong> ACE inhibitors are the treatment of choice for diabetic hypertension, particularly where microalbuminuria coexists. Thiazide diuretics and &beta;-blockers may worsen glycaemic control.</p>",
      "correct_choice_id": 223,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic autonomic neuropathy</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Transient ischemic attacks</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Arrhythmia</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Vasovagal syncope</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old male with 30 30-year history of type 1 DM presents with recurrent episodes of fainting and falls. He also reports erectile dysfunction and symptoms of GERD. On examination, he has a postural drop of 35 mmHg in his blood pressure. Which diagnosis fits best with his history and examination findings?</span></p>",
      "unique_key": "DT1186960",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186960,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The clinical features of significant postural blood pressure drop, gastrointestinal symptoms, and erectile dysfunction, in a patient with long-standing diabetes, are highly suggestive of <strong>diabetic autonomic neuropathy</strong>.</p>\n<p>Diabetic autonomic neuropathies occur secondary to dysfunction in the sympathetic and parasympathetic nervous systems in patients with long-standing DM.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918a8b31c71-08eb-4b76-82e0-8234652997fa.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Transient ischemic attacks (Option B):</strong> <strong>TIA</strong> is a brief episode of neurological dysfunction with a vascular cause, with clinical symptoms typically lasting less than one hour, and without evidence of infarction on imaging. While TIAs could explain falls, it does not account for GIT and urogenital symptoms.</p>\n<p><strong>Arrhythmia (Option C):</strong> Arrhythmias can present with syncope and can be easily ruled out with ECG. However, they usually do not cause the chronic symptoms of impotence and reflux.</p>\n<p><strong>Vasovagal syncope (Option D): </strong>Vasovagal syncope is usually associated with triggers like stress, pain, or prolonged standing. It is also not associated with other symptoms experienced in autonomic neutropathies.</p>",
      "correct_choice_id": 231,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">Losartan</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiazides</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">Gliclazide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old man with a history of myocardial infarction one year back presents for regular follow-up. He is both hypertensive and diabetic and complains of recent weight gain. Which of the following medications is likely responsible for his weight gain?</span></p>",
      "unique_key": "DT1186961",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186961,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Gliclazide belongs to the<strong> sulfonylurea </strong>class of oral hypoglycaemic drugs<strong>, </strong>which are commonly associated with weight gain.</p>\n<ul>\n<li>Sulfonylureas are oral hypoglycaemic drugs used in the management of type 2 diabetes mellitus.</li>\n<li>They work by increasing pancreatic insulin secretion and hence are only effective if functional beta-cells are present.</li>\n</ul>\n<p><strong>Common adverse effects</strong></p>\n<ul>\n<li><strong>Hypoglycaemic episodes</strong> (more common with long-acting preparations such as chlorpropamide)</li>\n<li>Weight gain</li>\n</ul>\n<p><strong>Rarer adverse effects</strong></p>\n<ul>\n<li><strong>Syndrome of inappropriate ADH secretion</strong></li>\n<li>Bone marrow suppression</li>\n<li>Liver damage (cholestatic)</li>\n<li>Photosensitivity</li>\n<li>Peripheral neuropathy</li>\n</ul>\n<p><strong>Contraindications: </strong></p>\n<ul>\n<li>Renal and hepatic insufficiency</li>\n<li>Avoided in breastfeeding and pregnancy</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Metformin (Option A): </strong>Metformin reduces fasting plasma glucose (FPG) and insulin levels, improves the lipid profile, and promotes modest weight loss.</p>\n<p><strong>Losartan (Option B): </strong>Losartan, an angiotensin II receptor blocker used for hypertension, is generally weight-neutral. They are used for blood pressure control in diabetic patients.</p>\n<p><strong>Thiazides (OptionC): </strong>Though thiazides have diabetogenic action, they can cause minimal or no weight loss due to transient fluid loss.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202404226c4bc621-9557-43ce-b2ca-b7914d4114e2.jpg\">",
      "correct_choice_id": 244,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}